

Special Issue

Genetic and Molecular Mechanisms of Cardiometabolic Diseases and Cancers—2nd Edition

Message from the Guest Editors

Cardiometabolic diseases (CMDs) and cancers, the two most prevalent non-communicable diseases globally, constitute major concerns worldwide. Recent evidence suggests close co-morbid linkages and shared risk factors between CMDs and cancers, calling for an integrated and systematic interrogation into their intercorrelation. Nevertheless, the mechanisms whereby genetic and other factors contribute to their co-occurrence remain unclear. Further research is therefore expected to provide novel insights into the genetic and molecular mechanisms underlying their correlations. Possible perspectives may involve shared genetic factors like genetic pleiotropy. In this Special Issue, we intend to take CMDs and cancers as examples to elucidate the intricate interconnections among complex diseases, and we welcome the submission of original high-quality research and review articles focused on (1) disease comorbidities; (2) genetic pleiotropy and heterogeneity; (3) genetic overlap and causality between CMD and cancers; and (4) indirect genetic effects.

Guest Editors

Prof. Dr. Tao Wu

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

Prof. Dr. Dafang Chen

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

Deadline for manuscript submissions

closed (31 December 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/212470

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).